异基因造血干细胞移植后巨细胞病毒感染易感因素及防治研究进展
Research Progress on Predisposing Factors and Prevention of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
DOI: 10.12677/ACM.2023.1391974, PDF,   
作者: 顾玉姣：青海大学临床医学院，青海 西宁；潘耀柱*：解放军联勤保障部队第九四〇医院血液科，甘肃 兰州
关键词: 异基因造血干细胞移植；巨细胞病毒；感染因素；预防及治疗；Allogeneic Hematopoietic Stem Cell Transplantation； Cytomegalovirus； Infection Factors； Prevention and Treatment
摘要: 异基因造血干细胞移植(allo-HSCT)是治疗恶性血液系统疾病最为有效的方法。而CMV感染是该过程后常见的感染性并发症之一，可能导致组织侵入性疾病，并增加移植后急、慢性移植物抗宿主病(GVHD)、其他机会性感染和医疗负担。这对发病率、死亡率和移植物存活率产生重大影响，甚至对患者构成致命风险。CMV终末器官疾病的致死率高，预后差。现已有定量诊断检测和治疗CMV的抗病毒疗法，但由于副作用和耐药性，应用受限。因此，如何保护患者平安度过感染的窗口期，是亟需解决的关键问题。本综述将就此问题进行讨论。
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective treatment for hematologic malignancies. CMV infection is a common infectious complication of the process, leading to tissue invasive disease and increasing post-transplant acute and chronic graft-versus-host dis-ease (GVHD), other opportunistic infections, and medical burden. This has a significant impact on morbidity, mortality, and graft survival, and even poses a fatal risk to patients. CMV end-organ dis-eases have a high fatality rate and poor prognosis. Antiviral therapies for the treatment of CMV are available for quantitative diagnostic testing and treatment, but their use is limited due to side ef-fects and drug resistance. Therefore, how to protect patients safely through the window of infection is a key issue that needs to be solved urgently. This review will discuss this issue.
文章引用：顾玉姣, 潘耀柱. 异基因造血干细胞移植后巨细胞病毒感染易感因素及防治研究进展[J]. 临床医学进展, 2023, 13(9): 14113-14121. https://doi.org/10.12677/ACM.2023.1391974

参考文献

[1] Fang, F.Q., Fan, Q.-S., Yang, Z.-J., Peng, Y.-B., Zhang, L, Mao, K.-Z., Zhang, Y. and Ji, Y.-H. (2009) Incidence of, Cytomegalovirus Infection in Shanghai, China. Clinical and Vaccine Immunology, 16, 1700-1703. [Google Scholar] [CrossRef] 
[2] 王朴英, 赵翔宇, 成娟, 刘蓓. 异基因造血干细胞移植后巨细胞病毒感染预防治疗的进展[J]. 中国感染与化疗杂志, 2022, 22(4): 515-520.
[3] Kaminski, H. and Fishman, J.A. (2016) The Cell Biology of Cytomegalovirus: Implications for Transplantation. American Journal of Transplantation, 16, 2254-2269. [Google Scholar] [CrossRef] [PubMed]
[4] Ljungman, P., et al. (2017) Definitions of Cytomegalovirus In-fection and Disease in Transplant Patients for Use in Clinical Trials. Clinical Infectious Diseases, 64, 87-91. [Google Scholar] [CrossRef] [PubMed]
[5] Chemaly, R.F., et al. (2019) Definitions of Resistant and Refractory Cyto-megalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clinical Infectious Diseases, 68, 1420-1426. [Google Scholar] [CrossRef] [PubMed]
[6] Yong, M.K., et al. (2020) New Advances in the Management of Cytomeg-alovirus in Allogeneic Haemopoietic Stem Cell Transplantation. Internal Medicine Journal, 50, 277-284. [Google Scholar] [CrossRef] [PubMed]
[7] Einsele, H., Ljungman, P. and Boeckh, M.J.B. (2020) How I Treat CMV Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 135, 1619-1629. [Google Scholar] [CrossRef] [PubMed]
[8] 朱成琳, 等. 儿童异基因造血干细胞移植术后巨细胞病毒感染临床分析[J]. 临床儿科杂志, 2020, 38(9): 641-646.
[9] Gao, X.-N., et al. (2020) Risk Factors and Associations with Clinical Outcomes of Cytomegalovirus Reactivation After Haploidentical versus Matched-Sibling Unmanipulated PBSCT in Patients with Hematologic Malignancies. Annals of Hematology, 99, 1883-1893. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, Y.-Y., et al. (2020) Comparable Survival Outcome be-tween Transplantation from Haploidentical Donor and Matched Related Donor or Unrelated Donor for Severe Aplastic Anemia Patients Aged 40 Years and Older: A Retrospective Multicenter Cohort Study. Clinical Transplantation, 34, e13810. [Google Scholar] [CrossRef] [PubMed]
[11] Dong, M.-Y., et al. (2020) Protective Effects of Cytomegalovirus DNA Copies ≥ 1000/mL for AML Patients in Complete Remission after Single Cord Blood Transplantation. Infection and Drug Resistance, 13, 373-383. [Google Scholar] [CrossRef] 
[12] Takenaka, K., et al. (2015) Cytomegalovirus Reactivation after Alloge-neic Hematopoietic Stem Cell Transplantation Is Associated with a Reduced Risk of Relapse in Patients with Acute My-eloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplanta-tion Transplantation-Related Complication Working Group. Transplantation and Cellular Therapy, 21, 2008-2016. [Google Scholar] [CrossRef] [PubMed]
[13] 上官思雨, 等. 异基因造血干细胞移植后巨细胞病毒感染的危险因素分析[J]. 临床血液学杂志, 2023, 36(5): 349-353.
[14] 黄金菊, 等. 亲属单倍型与同胞全相合HSCT后巨细胞病毒感染临床特点的比较[J]. 中华器官移植杂志, 2013, 34(2): 87-91.
[15] Hakki, M., et al. (2021) Ameri-can Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 27, 707-719. [Google Scholar] [CrossRef] [PubMed]
[16] Goldsmith, S.R., et al. (2021) Posttransplant Cyclophosphamide Is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis. Blood, 137, 3291-3305. [Google Scholar] [CrossRef] [PubMed]
[17] Marty, F.M., et al. (2017) Letermovir Prophylaxis for Cytomegal-ovirus in Hematopoietic-Cell Transplantation. Blood, 377, 2433-2444. [Google Scholar] [CrossRef] 
[18] Ljungman, P., et al. (2019) Guidelines for the Management Of Cy-tomegalovirus Infection in Patients with Haematological Malignancies and after Stem Cell Transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases, 19, e260-e272. [Google Scholar] [CrossRef] 
[19] Schmidt-Hieber, M., et al. (2010) Immune Reconstitution and Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation: The Important Impact of in Vivo T Cell Deple-tion. International Journal of Hematology, 91, 877-885. [Google Scholar] [CrossRef] [PubMed]
[20] Reusser, P., et al. (2002) Randomized Multicenter Trial of Fos-carnet Versus Ganciclovir for Preemptive Therapy of Cytomegalovirus Infection after Allogeneic Stem Cell Transplanta-tion: Presented in Part at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999 (Abstract H144). Blood, 99, 1159-1164. [Google Scholar] [CrossRef] 
[21] Ruiz-Camps, I., et al. (2011) Valganciclovir as Pre-Emptive Thera-py for Cytomegalovirus Infection in Allogeneic Haematopoietic Stem Cell Transplant Recipients. Antiviral Therapy, 16, 951-957. [Google Scholar] [CrossRef] 
[22] Maertens, J., et al. (2019) Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. New England Journal of Medicine, 381, 1136-1147. [Google Scholar] [CrossRef] 
[23] Fabrizio, V.A., et al. (2021) Adoptive Therapy with CMV-Specific Cytotoxic T Lymphocytes Depends on Baseline CD4+ Immunity to Mediate Durable Responses. Blood Advances, 5, 496-503. [Google Scholar] [CrossRef] [PubMed]
[24] Pei, X.-Y., et al. (2022) Comparable Anti-CMV Re-sponses of Transplant Donor and Third-Party CMV-Specific T Cells for Treatment of CMV Infection after Allogeneic Stem Cell Transplantation. Cellular & Molecular Immunology, 19, 482-491. [Google Scholar] [CrossRef] [PubMed]
[25] Pei, X.-Y., et al. (2022) Adoptive Therapy with Cytomegalovi-rus-Specific T Cells for Cytomegalovirus Infection after Haploidentical Stem Cell Transplantation and Factors Affecting Efficacy. American Journal of Hematology, 97, 762-769. [Google Scholar] [CrossRef] [PubMed]
[26] Kröger, N., et al. (2001) Patient Cytomegalovirus Seropositivity with or without Reactivation Is the Most Important Prognostic Factor for Survival and Treatment-Related Mortality in Stem Cell Transplantation from Unrelated Donors Using Pretransplant in Vivo T-Cell Depletion with Anti-Thymocyte Globulin. British Journal of Haematology, 113, 1060-1071. [Google Scholar] [CrossRef] [PubMed]

为你推荐